Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Screening Patterns and Mortality Differences in Patients With Lung Cancer at an Urban Underserved Community.

Su CT, Bhargava A, Shah CD, Halmos B, Gucalp RA, Packer SH, Ohri N, Haramati LB, Perez-Soler R, Cheng H.

Clin Lung Cancer. 2018 Jun 5. pii: S1525-7304(18)30139-6. doi: 10.1016/j.cllc.2018.05.019. [Epub ahead of print]

PMID:
29937386
2.

Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC).

Gadgeel SM, Pennell NA, Fidler MJ, Halmos B, Bonomi P, Stevenson J, Schneider B, Sukari A, Ventimiglia J, Chen W, Galasso C, Wozniak A, Boerner J, Kalemkerian GP.

J Thorac Oncol. 2018 Jul 17. pii: S1556-0864(18)30600-2. doi: 10.1016/j.jtho.2018.05.002. [Epub ahead of print]

PMID:
29775808
3.

Molecular Testing in Lung Cancer: Where to Draw the Line?

Halmos B.

Arch Pathol Lab Med. 2018 Jul;142(7):787-789. doi: 10.5858/arpa.2018-0060-ED. Epub 2018 Apr 6. No abstract available.

PMID:
29624077
4.

Biomarker use in lung cancer management: expanding horizons.

Sandler JE, Kaumaya M, Halmos B.

Biomark Med. 2018 Apr;12(4):315-320. doi: 10.2217/bmm-2018-0028. Epub 2018 Mar 23. No abstract available.

PMID:
29569465
5.

Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers.

Cheng H, Borczuk A, Janakiram M, Ren X, Lin J, Assal A, Halmos B, Perez-Soler R, Zang X.

Clin Cancer Res. 2018 Apr 15;24(8):1954-1964. doi: 10.1158/1078-0432.CCR-17-2924. Epub 2018 Jan 26.

PMID:
29374053
6.

Positron Emission Tomography-Adjusted Intensity Modulated Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.

Ohri N, Bodner WR, Kabarriti R, Shankar V, Cheng H, Abraham T, Halmos B, Gucalp R, Perez-Soler R, Kalnicki S, Garg M.

Int J Radiat Oncol Biol Phys. 2017 Oct 28. pii: S0360-3016(17)34039-7. doi: 10.1016/j.ijrobp.2017.10.032. [Epub ahead of print]

PMID:
29249527
7.

EGFR T790M: revealing the secrets of a gatekeeper.

Ko B, Paucar D, Halmos B.

Lung Cancer (Auckl). 2017 Oct 9;8:147-159. doi: 10.2147/LCTT.S117944. eCollection 2017. Review.

8.

Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistance.

Attarian S, Rahman N, Halmos B.

Ann Transl Med. 2017 Sep;5(18):377. doi: 10.21037/atm.2017.07.18. Review.

9.

Emerging uses of biomarkers in lung cancer management.

Halmos B, Levy B.

Ann Transl Med. 2017 Sep;5(18):370. doi: 10.21037/atm.2017.08.19. No abstract available.

10.

MET-GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors.

Smith MA, Licata T, Lakhani A, Garcia MV, Schildhaus HU, Vuaroqueaux V, Halmos B, Borczuk AC, Chen YA, Creelan BC, Boyle TA, Haura EB.

Clin Cancer Res. 2017 Nov 15;23(22):7084-7096. doi: 10.1158/1078-0432.CCR-16-3006. Epub 2017 Aug 29.

PMID:
28855353
11.

Efficacy and Safety Results of the Afatinib Expanded Access Program.

Kim ES, Halmos B, Kohut IF, Patel T, Rostorfer RD, Spira AI, Cseh A, McKay J, Wallenstein G, Mileham KF.

Oncol Ther. 2017;5(1):103-110. doi: 10.1007/s40487-017-0043-5. Epub 2017 Apr 10.

12.

DNA Polymerase ɛ Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity.

Castellucci E, He T, Goldstein DY, Halmos B, Chuy J.

Oncologist. 2017 May;22(5):497-502. doi: 10.1634/theoncologist.2017-0034. Epub 2017 May 2.

13.

Continuous Activity Monitoring During Concurrent Chemoradiotherapy.

Ohri N, Kabarriti R, Bodner WR, Mehta KJ, Shankar V, Halmos B, Haigentz M Jr, Rapkin B, Guha C, Kalnicki S, Garg M.

Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):1061-1065. doi: 10.1016/j.ijrobp.2016.12.030. Epub 2016 Dec 25.

14.

Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.

Schrock AB, Li SD, Frampton GM, Suh J, Braun E, Mehra R, Buck SC, Bufill JA, Peled N, Karim NA, Hsieh KC, Doria M, Knost J, Chen R, Ou SI, Ross JS, Stephens PJ, Fishkin P, Miller VA, Ali SM, Halmos B, Liu JJ.

J Thorac Oncol. 2017 Jun;12(6):932-942. doi: 10.1016/j.jtho.2017.03.005. Epub 2017 Mar 16.

15.

MET/HGF pathway activation as a paradigm of resistance to targeted therapies.

Ko B, He T, Gadgeel S, Halmos B.

Ann Transl Med. 2017 Jan;5(1):4. doi: 10.21037/atm.2016.12.09. Review.

16.

18F-Fluorodeoxyglucose/Positron Emission Tomography Predicts Patterns of Failure After Definitive Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.

Ohri N, Bodner WR, Halmos B, Cheng H, Perez-Soler R, Keller SM, Kalnicki S, Garg M.

Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):372-380. doi: 10.1016/j.ijrobp.2016.10.031. Epub 2016 Oct 26.

PMID:
28068244
17.

The Evolving Role of Biomarkers in Personalized Lung Cancer Therapy.

Sharma J, Shum E, Chau V, Paucar D, Cheng H, Halmos B.

Respiration. 2017;93(1):1-14. Epub 2016 Nov 29. Review. No abstract available.

18.

Marked Differences in CNS Activity among EGFR Inhibitors: Case Report and Mini-Review.

Pareek V, Welch M, Ravera E, Zampolin RL, Sequist LV, Halmos B.

J Thorac Oncol. 2016 Nov;11(11):e135-e139. doi: 10.1016/j.jtho.2016.07.010. Epub 2016 Jul 25. Review. No abstract available.

19.

Mutant allele specific imbalance in oncogenes with copy number alterations: Occurrence, mechanisms, and potential clinical implications.

Yu CC, Qiu W, Juang CS, Mansukhani MM, Halmos B, Su GH.

Cancer Lett. 2017 Jan 1;384:86-93. doi: 10.1016/j.canlet.2016.10.013. Epub 2016 Oct 8. Review.

20.

New twists in the AXL(e) of tumor progression.

Halmos B, Haura EB.

Sci Signal. 2016 Oct 4;9(448):fs14. Review.

PMID:
27703029
21.

Update in Lung Cancer 2015.

Spira A, Halmos B, Powell CA.

Am J Respir Crit Care Med. 2016 Sep 15;194(6):661-71. doi: 10.1164/rccm.201604-0898UP. No abstract available.

22.

HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.

Cheng H, Janakiram M, Borczuk A, Lin J, Qiu W, Liu H, Chinai JM, Halmos B, Perez-Soler R, Zang X.

Clin Cancer Res. 2017 Feb 1;23(3):825-832. doi: 10.1158/1078-0432.CCR-15-3071. Epub 2016 Aug 23.

23.

Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBPα expression.

Yong KJ, Basseres DS, Welner RS, Zhang WC, Yang H, Yan B, Alberich-Jorda M, Zhang J, de Figueiredo-Pontes LL, Battelli C, Hetherington CJ, Ye M, Zhang H, Maroni G, O'Brien K, Magli MC, Borczuk AC, Varticovski L, Kocher O, Zhang P, Moon YC, Sydorenko N, Cao L, Davis TW, Thakkar BM, Soo RA, Iwama A, Lim B, Halmos B, Neuberg D, Tenen DG, Levantini E.

Sci Transl Med. 2016 Aug 3;8(350):350ra104. doi: 10.1126/scitranslmed.aad6066.

PMID:
27488898
24.

An analysis of the relationship between metastases and cachexia in lung cancer patients.

Shiono M, Huang K, Downey RJ, Consul N, Villanueva N, Beck K, Fenn K, Dietz D, Yamaguchi T, Kato S, Divgi C, Kalinsky K, Wei Y, Zhang Y, Borczuk AC, Inoue A, Halmos B, Acharyya S.

Cancer Med. 2016 Sep;5(9):2641-8. doi: 10.1002/cam4.841. Epub 2016 Aug 3.

25.

Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.

Schrock AB, Frampton GM, Suh J, Chalmers ZR, Rosenzweig M, Erlich RL, Halmos B, Goldman J, Forde P, Leuenberger K, Peled N, Kalemkerian GP, Ross JS, Stephens PJ, Miller VA, Ali SM, Ou SH.

J Thorac Oncol. 2016 Sep;11(9):1493-502. doi: 10.1016/j.jtho.2016.06.004. Epub 2016 Jun 22.

26.

High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort.

Goel S, Hall J, Pradhan K, Hirsch C, Przychodzen B, Shastri A, Mantzaris I, Janakiram M, Battini R, Kornblum N, Derman O, Gritsman K, Al-Hafidh J, Wang Y, Halmos B, Steidl U, Maciejewski JP, Braunschweig I, Verma A.

Leukemia. 2016 Aug;30(8):1793-5. doi: 10.1038/leu.2016.74. Epub 2016 Apr 29. No abstract available.

PMID:
27125205
27.

Has MET met its match?

Borczuk A, Paucar D, Halmos B.

Ann Transl Med. 2016 Mar;4(5):97. doi: 10.21037/atm.2016.01.15. No abstract available.

28.

Recent advances in the management of pulmonary sarcomatoid carcinoma.

Shum E, Stuart M, Borczuk A, Wang F, Cheng H, Halmos B.

Expert Rev Respir Med. 2016 Mar 10:1-10. [Epub ahead of print]

PMID:
26962707
29.

Sunitinib activates Axl signaling in renal cell cancer.

van der Mijn JC, Broxterman HJ, Knol JC, Piersma SR, De Haas RR, Dekker H, Pham TV, Van Beusechem VW, Halmos B, Mier JW, Jiménez CR, Verheul HM.

Int J Cancer. 2016 Jun 15;138(12):3002-10. doi: 10.1002/ijc.30022. Epub 2016 Mar 1.

30.

Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells.

Cheng H, Zhang Z, Rodriguez-Barrueco R, Borczuk A, Liu H, Yu J, Silva JM, Cheng SK, Perez-Soler R, Halmos B.

Oncotarget. 2016 May 17;7(20):28976-88. doi: 10.18632/oncotarget.6721.

31.

RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.

Cheng H, Zou Y, Ross JS, Wang K, Liu X, Halmos B, Ali SM, Liu H, Verma A, Montagna C, Chachoua A, Goel S, Schwartz EL, Zhu C, Shan J, Yu Y, Gritsman K, Yelensky R, Lipson D, Otto G, Hawryluk M, Stephens PJ, Miller VA, Piperdi B, Perez-Soler R.

Cancer Discov. 2015 Dec;5(12):1262-70. doi: 10.1158/2159-8290.CD-14-0971. Epub 2015 Sep 14.

32.

Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer.

Halmos B, Pennell NA, Fu P, Saad S, Gadgeel S, Otterson GA, Mekhail T, Snell M, Kuebler JP, Sharma N, Dowlati A.

Oncologist. 2015 Nov;20(11):1298-303. doi: 10.1634/theoncologist.2015-0136. Epub 2015 Aug 25.

33.

Update in Lung Cancer 2014.

Spira A, Halmos B, Powell CA.

Am J Respir Crit Care Med. 2015 Aug 1;192(3):283-94. doi: 10.1164/rccm.201504-0756UP. Review.

34.

Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.

Liu X, Jia Y, Stoopler MB, Shen Y, Cheng H, Chen J, Mansukhani M, Koul S, Halmos B, Borczuk AC.

J Clin Oncol. 2016 Mar 10;34(8):794-802. doi: 10.1200/JCO.2015.62.0674. Epub 2015 Jul 27.

PMID:
26215952
35.

Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation?

Wang TJ, Saad S, Qureshi YH, Jani A, Nanda T, Yaeh AM, Rozenblat T, Sisti MB, Bruce JN, McKhann GM, Lesser J, Halmos B, Stoopler MB, Lassman AB, Cheng SK, Isaacson SR.

Neuro Oncol. 2015 Jul;17(7):1022-8. doi: 10.1093/neuonc/nov043. Epub 2015 Apr 24.

36.

PHLDA2 is a key oncogene-induced negative feedback inhibitor of EGFR/ErbB2 signaling via interference with AKT signaling.

Wang X, Li G, Koul S, Ohki R, Maurer M, Borczuk A, Halmos B.

Oncotarget. 2015 Apr 9;9(38):24914-24926. doi: 10.18632/oncotarget.3674. eCollection 2018 May 18.

37.

AXL kinase as a novel target for cancer therapy.

Wu X, Liu X, Koul S, Lee CY, Zhang Z, Halmos B.

Oncotarget. 2014 Oct 30;5(20):9546-63. Review.

38.

Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1.

Li G, Wang X, Hibshoosh H, Jin C, Halmos B.

PLoS One. 2014 Sep 19;9(9):e106349. doi: 10.1371/journal.pone.0106349. eCollection 2014.

39.

Molecular testing guidelines for lung adenocarcinoma: Utility of cell blocks and concordance between fine-needle aspiration cytology and histology samples.

Heymann JJ, Bulman WA, Maxfield RA, Powell CA, Halmos B, Sonett J, Beaubier NT, Crapanzano JP, Mansukhani MM, Saqi A.

Cytojournal. 2014 May 22;11:12. doi: 10.4103/1742-6413.132989. eCollection 2014.

40.

A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer.

Levy B, Spira A, Becker D, Evans T, Schnadig I, Camidge DR, Bauman JE, Hausman D, Walker L, Nemunaitis J, Rudin CM, Halmos B, Bowles DW.

J Thorac Oncol. 2014 Jul;9(7):1031-5. doi: 10.1097/JTO.0000000000000183.

41.
42.

The seventh door.

Halmos B.

Oncologist. 2014 May;19(5):574-5. doi: 10.1634/theoncologist.2014-0087. Epub 2014 Apr 10. No abstract available.

43.

Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer.

Sharma N, Pennell N, Nickolich M, Halmos B, Ma P, Mekhail T, Fu P, Dowlati A.

Invest New Drugs. 2014 Apr;32(2):362-8. doi: 10.1007/s10637-013-0061-6. Epub 2014 Jan 15.

PMID:
24420556
44.

Complete pathological response in a patient with metastatic esophageal cancer treated with a regimen of capecitabine, oxaliplatin and docetaxel: a case report.

Seetharamu N, Melamed J, Miller G, Rotterdam H, Gonda T, Villanueva G, Halmos B.

J Gastrointest Cancer. 2014 Dec;45 Suppl 1:108-11. doi: 10.1007/s12029-013-9575-6. No abstract available.

PMID:
24415222
45.

PIAS3 activates the intrinsic apoptotic pathway in non-small cell lung cancer cells independent of p53 status.

Dabir S, Kluge A, McColl K, Liu Y, Lam M, Halmos B, Wildey G, Dowlati A.

Int J Cancer. 2014 Mar 1;134(5):1045-54. doi: 10.1002/ijc.28448. Epub 2013 Sep 23.

46.

Update in lung cancer and mesothelioma 2012.

Powell CA, Halmos B, Nana-Sinkam SP.

Am J Respir Crit Care Med. 2013 Jul 15;188(2):157-66. doi: 10.1164/rccm.201304-0716UP. Review. No abstract available.

47.

EGFR molecular testing in African-American non-small cell lung cancer patients - a review of discrepant data.

Clifford BT, Fu P, Pennell NA, Halmos B, Leidner RS.

Transl Lung Cancer Res. 2013 Jun;2(3):251-5. doi: 10.3978/j.issn.2218-6751.2013.01.04. Review.

48.

A Phase I study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer.

Halmos B, Jia Y, Bokar JA, Fu P, Adelstein DJ, Juergens R, Rodal MB, Dowlati A.

Invest New Drugs. 2013 Oct;31(5):1244-50. doi: 10.1007/s10637-013-9945-8. Epub 2013 Apr 4.

PMID:
23553066
49.

PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.

Cheng H, Zhang Z, Borczuk A, Powell CA, Balajee AS, Lieberman HB, Halmos B.

Carcinogenesis. 2013 Apr;34(4):739-49. doi: 10.1093/carcin/bgs393. Epub 2012 Dec 28.

50.

Thymidylate synthase expression and molecular alterations in adenosquamous carcinoma of the lung.

Shu C, Cheng H, Wang A, Mansukhani MM, Powell CA, Halmos B, Borczuk AC.

Mod Pathol. 2013 Feb;26(2):239-46. doi: 10.1038/modpathol.2012.158. Epub 2012 Sep 21.

Supplemental Content

Loading ...
Support Center